Today, Sernova announced the exciting news that CCRM will be manufacturing its stem cell technology for diabetes, a disease which affects over 40 million patients. CCRM are experts in the stem cell manufacturing field and will be Sernova’s cell manufacturing arm.
Previously, in September 2015, Sernova announced it had signed a license agreement with the University Health Network (UHN) located in Toronto, Canada, for exclusive worldwide rights to specific technologies developed by two UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller. This cell manufacturing agreement executes Sernova’s worldwide exclusive license agreement to the Nostro/Keller technology and puts Sernova center stage within the diabetes space, where the company is actively working to secure large pharma partners.
This program is advancing in parallel to Sernova’s hemophilia program with multibillion dollar potential, in which a consortium of academic development partners and full non-dilutive funding ($8.5M Cdn) has been secured through the European Union’s Horizon 2020 grant mechanism. [Read more…]